Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

746
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
746
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

511
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
511

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cognitive decline in Dutch-type hereditary and sporadic cerebral amyloid angiopathy: a 5-year follow-up study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Impact of plasma pTau181 levels on clinician diagnostic confidence and management in memory and cognition clinics: A multi-site before-and-after study.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Exploring Experiences of Decision-Making for Appearance-Altering Lip/Nose Surgery in Adults Born With a Cleft Lip and/or Palate.

The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association·2026
Same author

Translational Feasibility of Curcumin for Treatment of Alzheimer's Disease: A Critical Appraisal of Clinical Challenges.

Antioxidants (Basel, Switzerland)·2026
Same author

Stage-dependent dynamics of neuroinflammation across the Alzheimer's continuum.

Brain, behavior, and immunity·2026
Same author

Circulating Sphingomyelins Correlate With Plasma T-Tau in Cognitively Unimpaired Older Adults at Risk of Developing Alzheimer's Disease.

Journal of neurochemistry·2026
Same journal

Patient-derived forebrain cortical organoids reveal biphasic tau-MAP6-microtubule axis dysfunction in tauopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Genetic architecture of the limbic white matter microstructure in aging and Alzheimer's Disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Greater choroid plexus volume is linked to poor sleep, neurodegeneration, and cognitive deficits in older adults: Evidence from the IGNITE Study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Plasma-based neurobiological protein biomarkers as predictors of dementia progression: Insights from longitudinal aging study in India - Diagnostic assessment of dementia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Neuropathology-specific language features in primary progressive aphasia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Dementia blood biomarkers in the context of post-stroke cognitive outcomes: Systematic review and evidence synthesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Grace Austin1, Shaun Eslick1, Jessica Ferguson2

  • 1Macquarie University, Macquarie Park, NSW, Australia.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 25, 2025
PubMed
Summary
This summary is machine-generated.

Higher cardiovascular disease (CVD) risk is linked to increased neurofilament light chain (NFL) levels, a marker of neurodegeneration. This suggests cardiovascular health may impact brain health and Alzheimer's disease (AD) pathways.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

Area of Science:

  • Neuroscience
  • Cardiology
  • Biomarker Research

Background:

  • Modifiable cardiovascular disease (CVD) risk factors are implicated in Alzheimer's disease (AD) pathogenesis.
  • These factors may contribute to cognitive decline and AD pathology through vascular mechanisms.
  • Limited research exists on the association between CVD risk and plasma AD biomarkers in cognitively normal individuals.

Purpose of the Study:

  • To investigate the association between predicted cardiovascular disease (CVD) risk and plasma Alzheimer's disease (AD) biomarkers.
  • To determine if CVD risk is linked to specific AD-related proteins in the blood.

Main Methods:

  • Cross-sectional analysis of 237 Australian adults (30-75 years).
  • Calculation of 5-year and 10-year CVD risk scores using established equations.
  • Measurement of plasma AD biomarkers (Aβ1-40, Aβ1-42, GFAP, NFL, pTau181) using SIMOA assays.
  • Partial correlation analysis adjusted for age and sex.

Main Results:

  • Higher predicted 5-year and 10-year CVD risk showed a significant positive correlation with neurofilament light chain (NFL) levels (r=0.22-0.23, p<0.001).
  • No significant correlations were found between CVD risk and GFAP, Aβ42/40 ratio, or pTau181.
  • No significant correlations were observed between cardiometabolic risk variables and other AD biomarkers.

Conclusions:

  • Elevated CVD risk is associated with increased NFL, a neurodegeneration biomarker, independent of age and sex.
  • This suggests that cardiovascular risk factors may significantly influence neurodegenerative pathways.
  • Further longitudinal studies are needed to explore the complex interactions between CVD risk and AD biomarkers.